Jane Street’s Acrivon Therapeutics ACRV Stock Holding History

Jane Street’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$133K	Sell	74,648 -165,043	-69%	-$280K	﹤0.01%	10436
2026 Q1	$333K	Sell	239,691 -102,380	-30%	-$179K	﹤0.01%	8995
2025 Q4	$824K	Buy	342,071 +52,823	+18%	+$115K	﹤0.01%	6552
2025 Q3	$524K	Sell	289,248 -22,581	-7%	-$31.7K	﹤0.01%	7765
2025 Q2	$371K	Buy	+311,829	New	+$428K	﹤0.01%	7471
2024 Q3	–	Sell	-30,714	Closed	-$178K	–	9488
2024 Q2	$178K	Buy	+30,714	New	+$247K	﹤0.01%	8481

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jane Street's ACRV Position: Q2 2026 in Review

Jane Street reduced its Acrivon Therapeutics (ACRV) stake by 69% in Q2 2026, selling an estimated $280K and leaving 74,648 shares worth $133K. The position accounts for ﹤0.01% of the portfolio, ranked #10436.

Jane Street first reported a position in ACRV in Q2 2024 and has held it in 6 quarters since. The position peaked at $824K in Q4 2025. 46 funds tracked by Wall St. Rank hold ACRV as of Q2 2026.

Jane Street held 74,648 shares of Acrivon Therapeutics worth $133K as of Q2 2026.
Jane Street sold 165,043 Acrivon Therapeutics shares in Q2 2026, an estimated $280K.
Acrivon Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #10436 holding.
Jane Street first reported a position in Acrivon Therapeutics in Q2 2024 and has held it in 6 quarters since.
Jane Street's Acrivon Therapeutics position peaked at $824K in Q4 2025.
46 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.